Notably, non-specific neuroinflammation and M1 polarization could be suppressed via inhibiting RAGE-NF-κB signaling pathway, implying VA potential as a therapeutic agent to target AD (139). This evidence concerns the gene NFKB1 and Alzheimer disease.